MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

35.66 2

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.39

Massimo

35.68

Metriche Chiave

By Trading Economics

Entrata

33M

-48M

Vendite

-2.6M

106M

Margine di Profitto

-45.487

Dipendenti

1,869

EBITDA

19M

-56M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+66.11% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

563M

3.9B

Apertura precedente

33.66

Chiusura precedente

35.66

Notizie sul Sentiment di mercato

By Acuity

50%

50%

157 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 lug 2025, 15:46 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lug 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 20:26 UTC

Utili

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lug 2025, 19:18 UTC

Discorsi di Mercato

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lug 2025, 19:03 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lug 2025, 18:31 UTC

Discorsi di Mercato

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lug 2025, 17:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk -2-

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lug 2025, 16:14 UTC

Acquisizioni, Fusioni, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lug 2025, 16:12 UTC

Discorsi di Mercato

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lug 2025, 16:08 UTC

Discorsi di Mercato

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lug 2025, 15:31 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250M Private Placement

9 lug 2025, 15:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lug 2025, 15:27 UTC

Discorsi di Mercato

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lug 2025, 14:36 UTC

Acquisizioni, Fusioni, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lug 2025, 14:31 UTC

Acquisizioni, Fusioni, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

66.11% in crescita

Previsioni per 12 mesi

Media 58.04 USD  66.11%

Alto 75 USD

Basso 38.2 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

5

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

157 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.